The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora NYSE: COR reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook.
Cencora, Inc. (COR) Q3 2026 Earnings Call Transcript
| Consumer Staples Distribution & Retail Industry | Consumer Staples Sector | Robert Mauch CEO | LSE Exchange | 03073E105 CUSIP |
| US Country | 49,000 Employees | 14 Aug 2026 Last Dividend | 16 Jun 2009 Last Split | 4 Apr 1995 IPO Date |
Cencora, Inc., previously known as AmerisourceBergen Corporation, is a global leader in healthcare solutions, with a focus on improving patient outcomes through the efficient distribution and commercialization of pharmaceuticals and healthcare-related products. Established in 2001 and headquartered in Conshohocken, Pennsylvania, Cencora has expanded its reach by providing a wide range of services to various healthcare providers, including acute care hospitals, retail pharmacies, mail order pharmacies, and specialists across numerous disease states. The company's commitment to offering comprehensive supply chain management services, specialized software, and consulting services underscores its integral role in the healthcare sector. Through its U.S. Healthcare Solutions and International Healthcare Solutions segments, Cencora, Inc. addresses the nuanced needs of its global client base, delivering tailored services that encompass distribution, commercialization, logistics, and much more.